What is the recommended treatment approach for mercury-associated membranous glomerulonephritis?

Mercury-Associated Membranous Glomerulonephritis: Treatment Approach

The primary treatment for mercury-associated membranous glomerulonephritis is immediate cessation of mercury exposure combined with chelation therapy; most patients achieve complete remission with chelation alone, though those with severe nephrotic syndrome or persistent disease after mercury removal may require additional immunosuppression with glucocorticoids and/or rituximab. 1, 2, 3

Initial Management: Mercury Removal and Chelation

Step 1: Eliminate Mercury Source

• Immediately discontinue all mercury-containing products (skin lightening creams, cosmetics, traditional medicines) 1, 2, 4
• Confirm mercury exposure with elevated serum mercury (normal <20 µg/L) and 24-hour urine mercury levels 1

Step 2: Chelation Therapy

• Initiate chelation therapy as the cornerstone of treatment 3, 4
• Use dimercaptosuccinic acid (DMSA) or dimercaptopropane-1-sulfonic acid (DMPS) depending on availability 1
• Multiple rounds of chelation may be necessary to normalize mercury levels 1, 4
• Chelation therapy alone achieves complete remission in approximately 56% of patients (14/25) with nephrotic syndrome 3

Risk Stratification for Additional Immunosuppression

Low-Risk Patients (Proteinuria Only, No Nephrotic Syndrome)

• Mercury detoxification monotherapy is typically sufficient 4
• Monitor for clinical improvement over 4-6 months 2

Moderate-Risk Patients (Nephrotic Syndrome with Stable Kidney Function)

• Chelation therapy plus glucocorticoids is the preferred approach 3
• This combination shows no significant difference in complete remission rates compared to chelation alone but may accelerate recovery 3
• Expected time to complete remission: median 1-4.5 months 2, 4

High-Risk Patients (Severe Nephrotic Syndrome or Persistent Disease)

• Chelation therapy plus glucocorticoids plus immunosuppressive therapy (rituximab or cyclophosphamide) 1, 3
• Consider this approach when:
  • Life-threatening nephrotic syndrome is present 5
  • Persistent immune complex glomerulonephritis on repeat biopsy despite normalized mercury levels 1
  • Failure to respond to chelation and glucocorticoids alone 1

Immunosuppression Protocols When Needed

Rituximab-Based Therapy

• Use standard rituximab dosing (1000 mg IV on days 1 and 15, or 375 mg/m² weekly for 4 weeks) 1
• May require multiple courses if initial treatment fails 1
• Particularly useful for NELL-1 positive mercury-associated MN 1, 6, 7

Modified Ponticelli Regimen

• Alternating monthly glucocorticoids with cyclophosphamide for 6 months 7
• Reserve for severe cases or rituximab failure 8, 5
• Monitor cumulative cyclophosphamide dose (limit to 25 g to minimize malignancy risk) 5

Key Distinguishing Features from Primary MN

Mercury-associated MN differs critically from primary membranous nephropathy:

• Negative for anti-PLA2R antibodies in serum and tissue (100% of cases) 2, 4
• Positive for NELL-1 antigen in many cases 1, 6, 7
• IgG1 and IgG4 predominant subclass deposition (rather than IgG4 alone) 4
• Excellent prognosis with no relapses after mercury withdrawal 2
• All patients achieve complete remission (unlike primary MN where spontaneous remission occurs in only 30-40%) 2

Treatment Monitoring

Clinical Response Indicators

• Median time to complete remission: 1-4.5 months after treatment initiation 2, 4
• Monitor proteinuria, serum albumin, and kidney function monthly 1
• Repeat mercury levels to confirm normalization 1

Duration of Therapy

• Median withdrawal time for immunosuppression: 26 months 2
• Unlike primary MN, patients can successfully discontinue all medications without relapse once mercury is eliminated 2
• No need for prolonged maintenance therapy typical of primary MN 2

Common Pitfalls to Avoid

Misdiagnosis as Primary MN

• Always obtain detailed exposure history for cosmetics, traditional medicines, and occupational exposures in any MN patient 6
• Test for mercury levels in all NELL-1 positive MN cases 6, 7
• Failure to identify mercury exposure leads to unnecessary prolonged immunosuppression 2

Inadequate Chelation

• Some patients require multiple rounds of chelation before mercury normalizes 1, 4
• Persistent immune complex disease may occur despite normalized mercury levels, requiring immunosuppression 1

Overtreatment

• Most patients respond to chelation alone or chelation plus glucocorticoids 3, 4
• Reserve aggressive immunosuppression (cyclophosphamide, rituximab) for truly severe or refractory cases 1, 3
• The overall effective rate is 97.5% with appropriate treatment 3

Prognosis

Mercury-associated MN has an excellent prognosis that is distinctly superior to primary MN:

• 100% complete remission rate with appropriate treatment 2
• No relapses after mercury withdrawal and drug discontinuation 2
• Median follow-up of 40 months shows sustained remission 2
• Normal kidney function preservation in most cases 3, 4